Endpoints News

FDA approves AbbVie's ultra-rare blood cancer ADC		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Thu F

28 May, 2026

ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.

Spotlight

Biopharma Sentiment Index | Q2 2026

news

GSK's functional cure data for hepatitis B drug are a major leap over standard of care

AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase

The ‘search for a magic bullet has faded’ in cancer immunotherapy. Here’s what’s next

May 28

11:30 am ET

From signal to strategy: The future of systemic viral immunotherapy in GI tumors and Oncolytics Biotech

sponsored by Samsung Biologics

A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.

ENDPOINTS PHARMA

WuXi Bio signs manufacturing deal with Viridian as Biosecure threat continues to erode

News Briefing

AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave

Signos raises $20M as it eyes health plan, pharma relationships

in case you missed it

Apogee lands $800M royalty deal with Blackstone to move Dupixent rival toward Phase 3

Post-Hoc Live: Jeremy Levin sounds the alarm on biotech

Kardigan readies Nasdaq IPO to back three cardio drugs

Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China

In Focus

Can AI do scientific research? Billions are pouring in to find out

Italy probes Biogen for allegedly hindering sales of rival's MS drug

Lilly vows global drug launches despite pricing pressure

We've got a big team going to Chicago for ASCO, which starts tomorrow. Keep a lookout for Lei Lei Wu, Max Gelman, Kyle LaHucik and Karen Weintraub. Stay tuned for our coverage over the weekend.

Reynald Castaneda

Deputy Editor, Endpoints News